CO2020010335A2 - Tratamiento de la rinitis alérgica en sujetos pediátricos con una combinación de mometasona y olopatadina - Google Patents

Tratamiento de la rinitis alérgica en sujetos pediátricos con una combinación de mometasona y olopatadina

Info

Publication number
CO2020010335A2
CO2020010335A2 CONC2020/0010335A CO2020010335A CO2020010335A2 CO 2020010335 A2 CO2020010335 A2 CO 2020010335A2 CO 2020010335 A CO2020010335 A CO 2020010335A CO 2020010335 A2 CO2020010335 A2 CO 2020010335A2
Authority
CO
Colombia
Prior art keywords
olopatadine
mometasone
allergic rhinitis
treatment
combination
Prior art date
Application number
CONC2020/0010335A
Other languages
English (en)
Inventor
Neelima Khairatkar-Joshi
Abhay Kulkarni
Dinesh Pradeep Wale
Vikram M Bhosale
Piyush Agarwal
Patrick Keohane
Sudeesh K Tantry
Chad Oh
Original Assignee
Glenmark Specialty Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/903,597 external-priority patent/US10758550B2/en
Application filed by Glenmark Specialty Sa filed Critical Glenmark Specialty Sa
Publication of CO2020010335A2 publication Critical patent/CO2020010335A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención hace referencia a un método para tratar la rinitis alérgica en un sujeto pediátrico que lo necesite que comprende administrar por vía nasal al sujeto una cantidad eficaz de una composición farmacéutica de dosis fija que comprende mometasona o su sal y olopatadina o su sal.
CONC2020/0010335A 2018-02-23 2020-08-21 Tratamiento de la rinitis alérgica en sujetos pediátricos con una combinación de mometasona y olopatadina CO2020010335A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/903,597 US10758550B2 (en) 2013-10-04 2018-02-23 Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PCT/IB2019/051465 WO2019162902A1 (en) 2018-02-23 2019-02-22 Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine

Publications (1)

Publication Number Publication Date
CO2020010335A2 true CO2020010335A2 (es) 2020-11-10

Family

ID=65818565

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0010335A CO2020010335A2 (es) 2018-02-23 2020-08-21 Tratamiento de la rinitis alérgica en sujetos pediátricos con una combinación de mometasona y olopatadina

Country Status (13)

Country Link
EP (1) EP3755375A1 (es)
JP (1) JP7391026B2 (es)
KR (1) KR20200125625A (es)
CN (1) CN111787954B (es)
AU (1) AU2019224850A1 (es)
BR (1) BR112020016817A2 (es)
CA (1) CA3088490A1 (es)
CO (1) CO2020010335A2 (es)
EA (1) EA202091744A1 (es)
MX (1) MX2020008741A (es)
PH (1) PH12020551311A1 (es)
SG (1) SG11202112592YA (es)
WO (1) WO2019162902A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
PE44995A1 (es) 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
AU2003291497B2 (en) * 2002-11-12 2007-12-20 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
PT2173169E (pt) * 2007-06-28 2014-09-03 Cydex Pharmaceuticals Inc Entrega nasal de soluções de corticosteróide aquosas
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
CN104173273A (zh) 2009-07-17 2014-12-03 爱尔康研究有限公司 儿童用奥洛他定鼻腔喷雾方案
CN102078326A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有聚维酮碘与糠酸莫米松的局部使用组合物
CN102078285A (zh) * 2009-11-26 2011-06-01 天津金耀集团有限公司 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
US9370483B2 (en) * 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10646500B2 (en) 2013-10-04 2020-05-12 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine

Also Published As

Publication number Publication date
CA3088490A1 (en) 2019-08-29
JP2021514947A (ja) 2021-06-17
CN111787954A (zh) 2020-10-16
AU2019224850A1 (en) 2020-08-13
KR20200125625A (ko) 2020-11-04
RU2020126691A (ru) 2022-03-23
WO2019162902A1 (en) 2019-08-29
EA202091744A1 (ru) 2021-01-15
CN111787954B (zh) 2023-09-05
JP7391026B2 (ja) 2023-12-04
EP3755375A1 (en) 2020-12-30
MX2020008741A (es) 2020-09-28
BR112020016817A2 (pt) 2020-12-15
PH12020551311A1 (en) 2021-09-06
SG11202112592YA (en) 2021-12-30
RU2020126691A3 (es) 2022-03-23

Similar Documents

Publication Publication Date Title
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015028432A2 (pt) aparelho e método para administração de uma prescrição de dispositivo médico
BR112017008093A2 (pt) processos para tratamento de doenças oculares
CO2019006292A2 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
BR112015020804A2 (pt) dispositivo fototerapeutico, método e uso
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112019006955A2 (pt) métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
AR101740A1 (es) Terapia de combinación y composiciones
BR112018067731A2 (pt) coagonistas de glucagon e glp-1 para o tratamento de obesidade
CL2019001415A1 (es) Composición para promover la diferenciación de y para proteger las células madre neuronales y método para inducir la regeneración neural utilizando la misma.
BR112014008036A2 (pt) tratamento de rinite
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
BR112017017502A2 (pt) dispositivo espaçador para o tratamento de um assento infectado no corpo humano
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112018011700A2 (pt) ?moduladores de canais de kv3 para tratar dor?
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112015027477A8 (pt) bolus, seus usos, e kit
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
CO2021008187A2 (es) Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica
BR112018012765A2 (pt) composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico.